CRISPR Therapeutics AG - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CRISPR Therapeutics AG on March 20, 2017. The report discloses a change in the Company's executive leadership structure effective March 21, 2017, specifically regarding the Chief Financial Officer role.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: Marc Becker, Senior Vice President and Chief Financial Officer, is going on a family and medical leave of absence effective March 21, 2017. An update on his status is expected before the end of the second quarter.
- Acting Appointments:
- Acting Principal Financial Officer: Samarth Kulkarni, Ph.D., currently the Chief Business Officer.
- Acting Principal Accounting Officer: Michael Esposito, currently the Senior Director, Controller.
Compensation and Employment Terms
The filing details the employment agreements for the newly appointed acting officers:
- Samarth Kulkarni, Ph.D.:
- Annual Base Salary: $370,800.
- Annual Bonus Target: 40% of base salary.
- Termination Provisions: Entitled to six months' notice (or 12 months if within 12 months of a change in control). Includes continued vesting and prorated bonus during the notice period. Garden leave begins 15 days after notice.
- Change in Control: Full acceleration of equity awards upon termination without cause or for good reason within specific windows relative to a change in control.
- Michael Esposito:
- Annual Base Salary: $228,375.
- Annual Bonus Target: 20% of base salary.
Investor Verification Checklist
- Confirm the duration of Marc Becker's leave and the timeline for his potential return.
- Review the Company's cash position to ensure it can sustain operations with the new compensation structure for acting officers.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Verify if the change in financial leadership impacts the Company's upcoming financial reporting schedule or audit processes.